Biotech and Pharmaceuticals Medicine

More

  • DNA Sequencing film strip.

    Intellia Therapeutics is hoping to transform the future of medicine with its gene-editing technology.

  • SAN DIEGO _ Tandem Diabetes Care Inc. on Thursday reported a loss of $18.3 million in its second quarter. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 65 cents per share. Seven analysts surveyed by Zacks expected $23.1 million.

  • NEW YORK, July 28- Celgene Corp raised its 2016 profit forecast and exceeded expectations for second-quarter earnings on Thursday on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines, sparking a 2 percent jump in its shares. Revlimid sales soared about 18 percent to $1.70 billion, above Wall Street's consensus estimate...

  • LONDON, July 28- Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter core earnings down by nearly a third at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes. Quarterly core earnings per share, which exclude some items, fell 31 percent to 83 cents as revenue slid 11 percent to $5.60...

  • NEW YORK— Boston Scientific's stock traded higher Thursday after the medical device maker reported better-than-expected second-quarter sales and raised its forecasts for the year. Boston Scientific Corp. bought American Medical Systems' male urology business for $1.6 billion almost a year ago, and as a result, revenue from its urology and pelvic-health...

  • NEW YORK— Israeli drugmaker Teva, the largest generic drug company in the world, said Wednesday it expects to complete its $40.5 billion purchase of the generic drug business of competitor Allergan next week after federal regulators approved the deal. The FTC said Allergan runs the third-largest generics company in the U.S. That business previously belonged...

  • Biomarin developing gene therapy for hemophilia

    CNBC's Meg Tirrell reports on a promising new treatment for hemophilia by Biomarin. And Kadmon has a tough first day of trading.

  • CHICAGO, July 27- TauRx Pharmaceuticals' experimental Alzheimer's drug LMTX failed to improve cognitive and functional skills in patients with mild to moderate Alzheimer's disease, a large, late-stage study showed. But the drug did show a benefit in a small group of patients who were not taking other standard Alzheimer's drugs, according to the findings...

  • ALS Ice Bucket Challenge makes a difference

    The ALS Association credits money raised from the Ice Bucket Challenge for the discovery of a gene related to the disease.

  • Ice bucket challenge

    The ALS Association is crediting money raised through the Ice Bucket Challenge for the discovery of an associated gene.

  • LONDON, July 27- GlaxoSmithKline has bought global rights to an experimental drug from Johnson& Johnson for up to 175 million pounds, raising its bet on a new generation of biotech medicines for severe asthma. The British drugmaker recently launched Nucala, its first injectable biological asthma drug, and is looking for additional treatments to help more...

  • Medical students and members of the public will be able to watch a live hernia surgery in 360-degree virtual reality (VR) later this week.

  • Certain jobs may help prevent Alzheimer's disease

    New research unveiled at the Alzheimer's Association International Conference stresses the importance of having complex careers or busy social lives.

  • Product sales fell to $7.65 billion from $8.13 billion in the year-ago quarter, Gilead said in a statement. Wall Street analysts, on average, had forecast hepatitis C sales of $4.09 billion, according to a poll by ISI Evercore. Gilead lowered its 2016 product sales outlook to between $29.5 billion and $30.5 billion, from a previous range of $30 billion to $31...

  • Quarterly net profit fell to $3.5 billion from $4.5 billion a year earlier. Adjusting for one-time items, Gilead earned $3.08 per share, which beat analysts' average estimate of $3.02, according to Thomson Reuters I/B/E/S. The company on Monday lowered its outlook for 2016 product sales to between $29.5 billion and $30.5 billion, from a previous range of $30...

  • LARAMIE, Wyo.— Work is underway at the Wyoming State Veterinary Laboratory to add a biohazard facility that will focus on the nasty diseases found in some Wyoming wildlife, like the plague and rabies. Director William Laegreid said the upgraded "biosafety level 3" laboratory will allow veterinarians to keep the main facility open when an animal shows up with a...

  • US Hospitals struggle to earn 5-star rating

    Federal health regulators say only about 2-percent of the nation's hospitals received the highest-quality rating.

  • Valeant Pharmaceuticals said U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida.

  • July 22- Valeant Pharmaceuticals International said on Friday U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch+ Lomb facility in Florida. The U.S. Food and Drug Administration, in a complete response letter regarding the eye drop for a type of glaucoma, raised concerns over Current Good Manufacturing Practice at the unit.

  • LONDON, July 22- Scientists are opening a new front in the war on cancer with plans to develop "anti-evolution" drugs to stop tumour cells from developing resistance to treatment. Britain's Institute of Cancer Research, one of the world's top cancer centres, said on Friday its initiative was the first to have at its heart the target of overcoming cancer evolution...